Wondering about the new code of conduct to be observed by drugmakers in the UK? Well, the Association of British Pharmaceutical Industry has released the details and, as we have seen in recent months, pharma’s favorite new buzzword - transparency - is used to describe the efforts.

The revisions call for drugmakers to make publicly available a short description of their support for patient organizations for both financial and significant indirect support; sponsorship declarations must accurately reflect the nature of the company’s involvement, and failure to disclose details of ongoing clinical trials will be considered a breach.

In addition, drugmakers will need to have a contract for health professionals and others employed as consultants, and are strongly encouraged to require consultants to declare this as an interest, and drugmakers are also encouraged to make publicly available information about donations and grants to institutions that support healthcare and research. This last bit is not a requirement, you will note.

Other changes include more guidance about meetings and hospitality; additional limitations on the supply of samples; publication of interim case reports when publication of the final report is delayed because the company’s procedures require audit, and ads for the outcome of certain cases will now appear in the nursing media as well as in medical and pharmaceutical journals.

Here is the complete code, which you can decipher for yourself.